Discovery of 3-n-butyl-2,3-dihydro-1H-isoindol-1-one as a potential anti-ischemic stroke agent

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 3377-3391

  Lan, Zujian ^a   Xu, Xiaoyu ^a   Xu, Wenkai ^a   Li, Jin ^a   Liang, Zengrong ^a   Zhang, Xuefei ^a   Lei, Ming ^a   Zhao, Chunshun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

3 alkyl 2; 3 dihydro 1H isoindol 1 ones; Ischemia reperfusion; Middle cerebral artery occlusion; Platelet aggregation; Stroke

Indexed keywords

3 ETHYL 2,3 DIHYDRO 1H ISOINDOL LEVO ONE; 3 ISOBUTYL 2,3 DIHYDRO 1H ISOINDOL LEVO ONE; 3 ISOPROPYL 2,3 DIHYDRO 1H ISOINDOL LEVO ONE; 3 N BUTYL 2 ETHYL 2,3 DIHYDRO 1H ISOINDOL LEVO ONE; 3 N BUTYL 2 METHYL 2,3 DIHYDRO 1H ISOINDOL LEVO ONE; 3 N BUTYL 2,3 DIHYDRO 1H ISOINDOL LEVO ONE; 3 N BUTYL 2,3- DIHYDRO 1H ISOINDOL LEVO ONE; 3 N HEXYL 2,3 DIHYDRO 1H ISOINDOL LEVO ONE; 3 N PENTYL 2,3 DIHYDRO 1H ISOINDOL LEVO ONE; 3 N PROPYL 2,3 DIHYDRO 1H ISOINDOL LEVO ONE; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ARACHIDONIC ACID; BUTYLPHTHALIDE; CARRAGEENAN; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; NITRIC OXIDE; NORPHENAZONE; REACTIVE OXYGEN METABOLITE; SCAVENGER; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; 3-N-BUTYL-2,3-DIHYDRO-1H-ISOINDOL-1-ONE; 3-N-BUTYLPHTHALIDE; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; BENZOFURAN DERIVATIVE; FIBRINOLYTIC AGENT; ISOINDOLE DERIVATIVE; NEUROPROTECTIVE AGENT; PHENAZONE; PHENYLMETHYLPYRAZOLONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ANTIPLATELET ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BRAIN; BRAIN DAMAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CANCER CELL LINE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL SURVIVAL; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG POTENCY; DRUG PURIFICATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HT22 CELL LINE; IC50; IN VITRO STUDY; MALE; MASS SPECTROMETRY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PERMANENT MIDDLE CEREBRAL ARTERY OCCLUSION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REPERFUSION INJURY; THROMBOCYTE AGGREGATION; THROMBOSIS; TRANSIENT MIDDLE CEREBRAL ARTERY OCCLUSION; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; BIOAVAILABILITY; BLOOD; CELL LINE; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; INFARCTION, MIDDLE CEREBRAL ARTERY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGY; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; ANTIOXIDANTS; ANTIPYRINE; BEHAVIOR, ANIMAL; BENZOFURANS; BIOLOGICAL AVAILABILITY; BRAIN; CARRAGEENAN; CELL LINE; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; ISOINDOLES; MALE; MICE; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSIS; TISSUE DISTRIBUTION;

EID: 84936865595     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S84731     Document Type: Article

References (55)

1. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–e292.
2. Khan M, Dhammu TS, Matsuda F, et al. Promoting endothelial function by S-nitrosoglutathione through the HIF-1α/VEGF pathway stimulates neurorepair and functional recovery following experimental stroke in rats. Drug Des Devel Ther. 2015;9:2233–2247.
3. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008;371:1612–1623.
4. Kraft P, Schwarz T, Meijers JCM, Stoll G, Kleinschnitz C. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke. PLoS One. 2010;5:e11658.
5. Mackman N. Triggers, Targets and treatments for thrombosis. Nature. 2008;451:914–918.
6. Zhang Y, Wang L, Li J, Wang XL. 2-(1-Hydroxypentyl)-benzoate increases cerebral blood flow and reduces infarct volume in rats model of transient focal cerebral ischemia. J Pharmacol Exp Ther. 2006;317:973–979.
7. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology. 2008;55:363–389.
8. Pandya RS, Mao L, Zhou H, et al. Central nervous system agents for ischemic stroke: neuroprotection mechanisms. Cent Nerv Syst Agents Med Chem. 2011;11:81–97.
9. Bouckaert M, Lemmens R, Thijs V. Reducing prehospital delay in acute stroke. Nat Rev Neurol. 2009;5:477–483.
10. van den Berg JS, de Jong G. Why ischemic stroke patients do not receive thrombolytic treatment: results from a general hospital. Acta Neurol Scand. 2009;120:157–160.
11. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147–152.
12. Tuttolomondo A, Pecoraro R, Pinto A. Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date. Drug Des Devel Ther. 2014;8:2221–2239.
13. Harukuni I, Bhardwaj A. Mechanisms of brain injury after global cerebral ischemia. Neurol Clin. 2006;24:1–21.
14. Wang T, Gu J, Wu PF, et al. Protection by tetrahydroxystilbene glucoside against cerebral ischemia: involvement of JNK, SIRT1, and NF-kappaB pathways and inhibition of intracellular ROS/RNS generation. Free Radic Biol Med. 2009;47:229–240.
15. Candelario-Jalil E. Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neuro-therapeutics. Curr Opin Invesigt Drugs. 2009;10:644–654.
16. Murakami K, Kondo T, Kawase M, et al. Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency. J Neurosci. 1998;18:205–213.
17. Suzuki K. Anti-oxidants for therapeutic use: why are only a few drugs in clinical use? Adv Drug Deliv Rev. 2009;61:287–289.
18. Liu CL, Liao SJ, Zeng JS, et al. DL-3-n-butylphthalide prevents stroke via improvement of cerebral microvessels in RHRSP. J Neurol Sci. 2007;260:106–113.
19. Peng Y, Zeng X, Feng Y, Wang X. Antiplatelet and antithrombotic activity of L-3-n-butyphthalide in rats. J Cardiovasc Pharmacol. 2004;43:876.
20. Li L, Zhang B, Tao Y, et al. DL-3-n-butylphthalide protects endothelial cells against oxidative/nitrosative stress, mitochondrial damage and subsequent cell death after oxygen glucose deprivation in vitro. Brain Res. 2009;1290:91–101.
21. Wang XL, Li Y, Zhao Q, et al. Design, synthesis and evaluation of nitric oxide releasing derivatives of 3-n-butylphthalide as antiplatelet and antithrombotic agents. Org Biomol Chem. 2011;9:5670–5681.
22. Zhao C, He Z, Cui S, Zhang R. Determination of 3-n-butylphthalide in rabbit plasma by HPLC with fluorescence detection and its application in pharmacokinetic study. Biomed Chromatogr. 2003;17:391–395.
23. Xu B, Zhao Z. Butylphthalide injection, an innovative drug originated in China for the treatment of ischemic stroke. Chin J New Drugs. 2011;20:11.
24. Zhao C. Studies on Pharmacokinetics of 3-n-Butylphthalide in Rats and Rabbits and the Transport Mechanism in Brain [doctorate thesis]. Shenyang: Shenyang Pharmaceutical University; 2003.
25. Lu R. The Comparative Study on Pharmacokinetics of R- and S-isomers of NBP in Beagle Dogs [master thesis]. Tianjin: Tianjin Medical University; 2006.
26. Zhu Y, Tan S. Observation of DL-3-n-butylphthalide combined edarovone treating 36 patients with progressive cerebral infarction. Chin J Pract Nerv Dis. 2010;13:10–12.
27. Belliotti TR, Brink WA, Kesten SR, et al. Isoindolinone enantiomers having affinity for the dopamine D4 receptor. Bioorg Med Chem Lett. 1998;8:1499–1502.
28. Drutu I, Hurley DJ, Bandarage UK, et al, inventor; Vertex Pharmaceuticals Incorporated, USA., assignee. Spiropiperidine derivatives as modulators of muscarinic receptors and their preparation, pharmaceutical composition and use for treatment of muscarinic receptor-mediated diseases. United States patent US 20060270653. 2006 Nov 30.
29. Greig NH, Holloway H, Brossi A, et al, inventor; The Secretary of the Department of Health and Human Services, USA., assignee. Preparation of thalidomide analogs as modulators of TNF-α activity and angiogenesis. United States patent US 20060211728. 2006 Sep 21.
30. Carry JC, Mignani S, Bigot A, Ronan B, Kleemann HW, Hofmeister A, inventor; Aventis Pharma Sa, Fr, assignee. Preparation of isoindolones as NHE (sodium/hydrogen exchanger) inhibitors, and their pharmaceutical compositions used as cytoprotective agents. United States patent US 20040048916. 2004 Mar 11.
31. Tweedie D, Giordano T, Yu QS. TNF-α synthesis inhibitors on the 3-phthalimidoglutarimide backbone as therapeutic candidates for neurodegenerative diseases. In: 7th International Conference on Alzheimer’s and Parkinson’s Disease; March 9–13, 2005; Sorrento, Italy. Bologna: Monduzzi Editore; 2005:77–86.
32. Hagmann WK, Lin LS, Shah SK, et al, inventor; Merck & Co., Inc., USA., assignee. Preparation of substituted amides as antagonists and/or inverse agonists of the cannabinoid-1 receptor for therapy. United States patent US 20040058820. 2004 Mar 25.
33. Sheridan JM, Heal JR, Hamilton WDO, Pike I, inventor; Electrophoretics Limited, UK., assignee. Casein kinase 1δ inhibitors for the treatment of neurodegenerative disorders. United States patent US 20140018540. 2014 Jan 16.
34. Amberg W, Lange U, Ochse M, et al, inventor; AbbVie Inc., USA; AbbVie Deutschland GmbH & Co. KG., assignee. Preparation of isoindoline derivatives and their use in therapy. United States patent US 20130210880. 2013 Aug 15.
35. Born GVR, Cross MJ. The aggregation of blood platelets. Physiology. 1963;168:178.
36. Bertelli A, Giovannini L, Galmozzi G, Bertelli AA. Protective role of propionyl carnitine in vascular disorders experimentally induced by endothelin (ET-1) serotonin and K-carrageenin. Drugs Exp Clin Res. 1993;19:7–11.
37. Longa EZ, Weinstein PR, Carlson S. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84–91.
38. Ashwal S, Tone B, Tian HR, Cole DJ, Pearce WJ. Core and penumbral nitric oxide synthase activity during cerebral ischemia and reperfusion. Stroke. 1998;29:1037–1046.
39. Ruan YP, Chen MD, He MZ, Zhou X, Huang PQ. A practical two-step synthesis of 3-alkyl-2,3-dihydro-1H-isoindolin-1-ones. Synth Commun. 2004;34:853–861.
40. Ye JQ, Zhai LL, Zhang SH, et al. DL-3-n-butylphthalide inhibits platelet activation via inhibition of cPLA2-mediated TXA2 synthesis and phosphodiesterase. Platelets. 2015;3:1–9.
41. Ma FF, G Y, Q HL, H XJ, C JB. Antiplatelet activity of 3-butyl-6-bromo-1(3H)-isobenzofuranone on rat platelet aggregation. J Thromb Thrombolysis. 2012;33:64–73.
42. Zhao WH, Luo C, Wang J, et al. 3-N-butylphthalide improves neuronal morphology after chronic cerebral ischemia. Neural Regen Res. 2014;9:719–726.
43. Zhao Q, Zhang C, Wang XL, Chen L, Ji H, Zhang YH. (S)-ZJM-289, a nitric oxide-releasing derivative of 3-n-butylph-thalide, protects against ischemic neuronal injury by attenuating mitochondrial dysfunction and associated cell death. Neurochem Int. 2012;60:134–144.
44. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging. 2001;18:685–716.
45. Moosmann B, Behl C. Antioxidants as treatment for neurodegenerative disorders. Expert Opin Investig Drugs. 2002;11:1407–1435.
46. Iadecola C, Zhang FY, Casey R, Clark HB, Ross ME. Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke. 1996;27:1373–1380.
47. Talalay P, Dinkova-Kostova AT, Holtzclaw WD. Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis. Adv Enzyme Regul. 2003;4:121–134.
48. Skutella T, Lezoualc’h F, Post A, Widmann M, Newton CJ, Holsboer F. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol. 1997;51:535–541.
49. Dargusch R, Schubert D. Specificity of resistance to oxidative stress. J Neurochem. 2002;81:1394–1400.
50. Moosmann B, Behl C. The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc Natl Acad Sci U S A. 1999;96:8867–8872.
51. Sagara Y, Hendler S, Khoh-Reiter S, et al. Propofol hemisuccinate protects neuronal cells from oxidative injury. J Neurochem. 1999;73:2524–2530.
52. Tan S, Somia N, Maher P, Schubert D. Regulation of antioxidant metabolism by translation initiation factor 2alpha. J Cell Biol. 2001;152:997–1006.
53. Dirnagl U, Lindauer U, Them A, et al. Global cerebral ischemia in the rat: online monitoring of oxygen free radical production using chemiluminescence in vivo. J Cereb Blood Flow Metab. 1995;15:929–940.
54. Lancelot E, Callebert J, Revaud ML, Boulu RG, Plotkine M. Detection of hydroxyl radicals in rat striatum during transient focal cerebral ischemia: possible implication in tissue damage. Neurosci Lett. 1995;197:85–88.
55. Malinski T, Bailey F, Zhang ZG, Chopp M. Nitric oxide measured by a porphyrinic microsensor in rat brain after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1993;13:355–358.